Treatment of Genotype 1 HCV Infection in the HIV Coinfected Patient in 2014

被引：0
|
作者：
Cody A. Chastain
Susanna Naggie
机构：
[1] Vanderbilt University Medical Center,Division of Infectious Diseases
[2] Division of Infectious Diseases,undefined
[3] Duke Clinical Research Institute,undefined
来源：
Current HIV/AIDS Reports | 2013年 / 10卷
关键词：
Hepatitis C; HIV; HIV-HCV coinfection; Telaprevir; Boceprevir; Sofosbuvir; Simeprevir; Faldaprevir; Daclatasvir;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Hepatitis C (HCV) coinfection is the leading cause of liver-related morbidity and is a leading cause of mortality in human immunodeficiency virus (HIV)-infected individuals in the antiretroviral therapy era. Direct-acting antiviral (DAA) therapies are transforming how HCV is treated with significant improvements in efficacy and tolerability. In this article, DAA agents expected to be available in 2014 are reviewed, including telaprevir, boceprevir, sofosbuvir, simeprevir, faldaprevir, and daclatasvir. Available data regarding clinical efficacy, adverse effects, and drug interactions in HIV-HCV coinfection are discussed. The management of adverse effects of HCV therapy and treatment considerations in patients with cirrhosis are also reviewed.
引用
收藏
页码：408 / 419
页数：11
相关论文
共 50 条
  • [1] Treatment of Genotype 1 HCV Infection in the HIV Coinfected Patient in 2014
    Chastain, Cody A.
    Naggie, Susanna
    CURRENT HIV/AIDS REPORTS, 2013, 10 (04) : 408 - 419
  • [2] The HIV/HCV-Coinfected Patient and New Treatment Options
    Vachon, Marie-Louise C.
    Dieterich, Douglas T.
    CLINICS IN LIVER DISEASE, 2011, 15 (03) : 585 - +
  • [3] Approach to the Treatment-naive Patient with HCV Genotype 1 Infection
    Muir, Andrew J.
    INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2012, 26 (04) : 893 - +
  • [4] Evaluation and treatment of the HIV/HCV coinfected patient: A case history and discussion
    McGovern, B
    AIDS PATIENT CARE AND STDS, 2002, 16 (07) : 319 - 326
  • [5] Management of the HIV-HCV coinfected patient
    Mutimer, D
    GUT, 2000, 47 (05) : 608 - 609
  • [6] Use of first-generation HCV protease inhibitors in patients coinfected by HIV and HCV genotype 1
    Salmon-Ceron, Dominique
    Arvieux, Cedric
    Bourliere, Marc
    Cacoub, Patrice
    Halfon, Philippe
    Lacombe, Karine
    Pageaux, Georges-Philippe
    Pialoux, Gilles
    Piroth, Lionel
    Poizot-Martin, Isabelle
    Rosenthal, Eric
    Pol, Stanislas
    LIVER INTERNATIONAL, 2014, 34 (06) : 869 - 889
  • [7] USE OF SOFOSBUVIR/LEDIPASVIR FIXED DOSE COMBINATION FOR TREATMENT OF HCV GENOTYPE-1 IN PATIENTS COINFECTED WITH HIV
    Osinusi, A.
    Townsend, K.
    Nelson, A.
    Kohli, A.
    Gross, C.
    Polis, M. A.
    Pang, P. S.
    Symonds, W. T.
    Talwani, R.
    Sajadi, M. M.
    Hogan, J.
    Benator, D.
    Subramanian, M.
    Mchutchison, J.
    Masur, H.
    Kottilil, S.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S7 - S7
  • [8] HCV GENOTYPE 1 AND 4 TREATMENT IN LIVER TRANSPLANTED AND IN HIV COINFECTED PATIENTS: EFFECTS OF IMMUNOSUPPRESSION ON THE RESPONSE TO THERAPY
    Ponziani, Francesca R.
    Di Giambenedetto, Simona
    Siciliano, Massimo
    Annicchiarico, Eleonora Brigida
    Pompili, Maurizio
    Caracciolo, Gianluigi
    Dal Verme, Lorenzo Zileri
    Tamburrini, Enrica
    Farina, Salvatore
    De Luca, Andrea
    Fagiuoli, Stefano
    Gasbarrini, Antonio
    HEPATOLOGY, 2010, 52 (04) : 800A - 800A
  • [9] HCV GENOTYPE 1 AND 4 TREATMENT IN LIVER TRANSPLANTED AND IN HIV COINFECTED PATIENTS: EFFECTS OF IMMUNOSUPPRESSION ON THE RESPONSE TO THERAPY
    Ponziani, F. R.
    Di Giambenedetto, S.
    Siciliano, M.
    Annicchiarico, B. E.
    Pompili, M.
    Caracciolo, G.
    Dal Verme, L. Zileri
    Tamburrini, E.
    Farina, S.
    De Luca, A.
    Gasbarrini, A.
    Aisf, R. G.
    DIGESTIVE AND LIVER DISEASE, 2011, 43 : S213 - S213
  • [10] Challenges in the treatment of chronic hepatitis C in the HIV/HCV-coinfected patient
    Rodriguez-Torres, Maribel
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2012, 10 (10) : 1117 - 1128
12345